$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Which generation of targeted drugs does Osimertinib (Tagrisso) belong to and its target description
2026-02-01 22:25:32
Check Details
Is there a risk of platelet decline while taking Eltrombopag (Revlan)?
2026-02-01 22:25:32
Check Details
Guidelines for the best taking time and medication intervals of Roprostim (Huierning)
2026-02-01 22:25:32
Check Details
Analysis of which disease types and patient populations Midostaurin is suitable for
2026-02-01 22:25:32
Check Details
Analysis of the main functions and clinical applications of cabergoline
2026-02-01 22:25:32
Check Details
Standard dosage and safe medication recommendations for Momelotinib
2026-02-01 22:25:32
Check Details
Common side effects and symptoms of Biken Pronol Tablets (Bituvi)
2026-02-01 22:25:32
Check Details
Detailed instructions and medication guide for decavatinib
2026-02-01 22:25:32
Check Details
What is the actual efficacy of Apremilast (Otelac)? Patient feedback and clinical observations
2026-02-01 22:25:32
Check Details
What kind of drugs does Valganciclovir belong to and its clinical pharmacological effects?
2026-02-01 22:25:32
Check Details
Analysis of the efficacy of Shafinamide Tablets (Siddaco) and its clinical efficacy in Parkinson’s patients
2026-02-01 22:25:32
Check Details
Tarlatamab-Imdelltra official instructions and instructions for use
2026-02-01 22:25:32
Check Details
1
2
...
2260
2261
2262
2263
2264
2265
2266
...
10214
10215
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Niraparib: A PARP Inhibitor for Ovarian Cancer Maintenance Therapy
2
Abiraterone Acetate: CYP17 Inhibitor for Advanced Prostate Cancer
3
Plerixafor: Mobilizing Hematopoietic Stem Cells for Autologous Transplantation
4
Brensoctib: Managing Side Effects of the Novel DPP-1 Inhibitor for Bronchiectasis
5
Tivozanib: The Evolution of Highly Selective VEGFR Inhibition in Renal Cell Carcinoma
6
Trifluridine/Tipiracil: Managing Side Effects in Metastatic Colorectal and Gastric Cancer
7
Trelagliptin: The First Once-Weekly DPP-4 Inhibitor Revolutionizing Type 2 Diabetes Care
8
Adagrasib Medication Management Guide for Special Populations
9
Olutasidenib (Rezlidhia): A Targeted Drug for IDH1-Mutated Relapsed/Refractory AML
10
Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer
11
FDA Approves Dual Immunotherapy Combo: Tecvayli + Darzalex Faspro Transforms RRMM Treatment
12
Cabozantinib: Pivotal Advancements and Global Implications in Multi-Cancer Treatment with Multi-Kinase Inhibition